

Volume contents

iii

Volume 1, Number 1, 1990

1 Editorial

MiniReview

- 3 **Targets for antiviral chemotherapy: HIV-proteinase**
B. M. Dunn & J. Kay
- 9 **HIV-1 aspartic proteinase: high-level production and automated fluorometric screening assay of inhibitors**
Ph.-H. Hirel, F. Parker, J. Boiziau, G. Jung, D. Outerovitch, A. Dugué, C. Peltiers, C. Giuliani, R. Boulay, Y. Lelièvre, B. Cambou, J.-F. Mayaux & T. Cartwright
- 17 **New virus-selective inhibitor of terminal glycosylation increasing immunological reactivity of a viral glycoprotein**
S. Olofsson & R. Datema
- 25 **Synthesis of some novel dialkyl phosphate derivatives of 3'-modified nucleosides as potential anti-AIDS drugs**
C. McGuigan, S. R. Nicholls, T. J. O'Connor & D. Kinchington
- 35 **E-5-(2-chlorovinyl)-2'-deoxycytidine: synthesis and antiherpetic activity**
A. Kumar, M. Lewis, S.-I. Shimizu, R. T. Walker, R. Snoeck & E. De Clercq
- 41 **Sulphated sugar alpha-cyclodextrin sulphate, a uniquely potent anti-HIV agent, also exhibits marked synergism with AZT, and lymphoproliferative activity**
R. Anand, S. Nayyar, J. Pitha & C. R. Merrill
- 47 **Intranasal treatment of picornavirus and coronavirus respiratory infections in rodents using 7-thia-8-oxoguanosine**
D. F. Smee, H. A. Alaghamandan, M. L. Bartlett & R. K. Robins
- 53 **Modulation of the antiviral activity of poly(A-U) by ethidium bromide and propidium iodide**
J. M. Jamison, P. J. Bonilla & C.-C. Tsai
- 61 **Inhibitory effects of heterogeneous dextran sulphate compounds on simian type D retrovirus *in vitro***
C.-C. Tsai, K. E. Follis & M. Yarnall
- 67 **Targets of amphotericin B methyl ester (AME) in the inhibition of infection of different cell lines by HIV-1**
D. Pontani, O. J. Plescia, C. P. Shaffner, D. Sun, S. I. Shahied & P. S. Sarin

Letter to the Editor

- 73 **On the specificity of the gp120-CD4 binding reaction**
Y. Morikawa, K. Ohki, K. Ikuta & I. Jones

Volume 1, Number 2, 1990

Review

- 75 **A therapeutic panorama of the spongiform encephalopathies**
P. Brown

MiniReview

- 85 **Targets for antiviral chemotherapy: HIV regulatory proteins**
S. M. Kingsman & A. J. Kingsman
- 93 **The crystal and molecular structure of 3'-fluoro-3'-deoxythymidine, a potent anti-HIV-1 nucleoside**
P. Van Roey & R. F. Schinazi
- 99 **The galactose-specific lectin from the sponge *Chondrilla nucula* displays anti-human immunodeficiency virus activity *in vitro* via stimulation of the (2'-5') oligoadenylate metabolism**
H. C. Schröder, Z. Kljajić, B. E. Weiler, M. Gasić, G. Uhlenbruck, B. Kurelec & W. E. G. Müller
- 107 **Synthesis and evaluation of some novel phosphoramidate derivatives of 3'-azido-3'-deoxythymidine (AZT) as anti-HIV compounds**
C. McGuigan, K. G. Devine, T. J. O'Connor, S. A. Galpin, D. J. Jeffries & D. Kinchington
- 115 ***In vitro* studies of the antiviral range of ciclohexolone sodium and identification of cell lines tolerant to the drug**
C. Galt, D. J. Dargan & J. H. Subak-Sharpe
- 125 **Antiviral activity of mixtures of compounds against herpesviruses**
L. A. T. Al-Nisairawi, V. Guadagnin, R. Jennings & C. W. Potter
- 131 **Investigation of topoisomerase inhibitors for activity against human immunodeficiency virus: inhibition by coumermycin A1**
G. Tachedjian, D. Tyssen, S. Locarnini, I. Gust & C. Birch
- 139 **Exploitation of a rapid and sensitive assay to analyse transactivation of the human immunodeficiency virus type 1 (HIV-1) long terminal repeat**
C. M. Roberts & E. D. Blair
- 149 **Isolation and preliminary characterization of chalcone RO 09-0410-resistant human rhinovirus type 2**
S. R. Yasin, W. Al-Nakib & D. A. J. Tyrrell
- 155 **Comparison of the intracellular metabolism of 3'-azido-3'-deoxythymidine and 3'-fluoro-3'-deoxythymidine in lymphocytes in the presence of 5-fluoro-2'-deoxyuridine**
S. Cox & J. Harmenberg

Volume 1, Number 3, 1990

Feature article

- 163 **A stereochemical rationale for the activity of anti-HIV nucleosides**
E. W. Taylor, P. Van Roey, R. F. Schinazi & C. K. Chu
- 175 **Characterization of gp120 binding to the CD4 antigen and detection of specific inhibitors**
M. R. Kozlowski & A. Watson
- 183 **Synthesis of 2' and 3'-amino-substituted uridine, thymidine and adenosine, and their inhibitions of HIV replication**
J.-M. Vial, N. G. Johansson, L. Vrang & J. Chattopadhyaya
- 203 **Flavonoids: potent inhibitors of poliovirus RNA synthesis**
M. E. González, F. Martínez-Abarca & L. Carrasco
- 211 **Inhibition of *Phlebovirus* infections *in vivo* by tiazofurin and selenazofurin**
D. F. Smee, J. H. Huffman, L. L. Hall, J. W. Huggins & R. W. Sidwell
- 217 ***In vitro* antiviral activity and cytotoxicity of aspirin: lack of selective activity against influenza A virus or rhinovirus**
C. E. Crump, B. S. Rollins & F. G. Hayden

Short communication

- 223 **Stability of the herpesvirus ribonucleotide reductase-inhibiting nonapeptide YAGAVNDL in extracts of HSV-1-infected cells**
E. Telford, A. Owsianka & H. Marsden

Volume 1, Number 4, 1990

MiniReview

- 227 **Aetiology of hantavirus infections**
G. Lloyd
- 233 **Sulphated polymers are potent and selective inhibitors of various enveloped viruses, including herpes simplex virus, cytomegalovirus, vesicular stomatitis virus, respiratory syncytial virus, and toga-, arena- and retroviruses**
D. Schols, E. De Clercq, J. Balzarini, M. Baba, M. Witvrouw, M. Hosoya, G. Andrei, R. Snoeck, J. Neyts, R. Pauwels, M. Nagy, J. György-Edelényi, R. Machovich, I. Horváth, M. Lów & S. Görög
- 241 **A comparison of pyrimidinone analogue immunomodulators for treatment of *Phlebovirus* infections in mice**
R. W. Sidwell, J. H. Huffman, J. Coombs, H. Renis, J. Huggins & M. Kende

- 249 **The enzymatic synthesis and anti-HIV-1 activity of 9- β -D-2',3'-dideoxynucleosides of N(6)-substituted purines**
D. Betbeder, D. W. Hutchinson, A. O'L. Richards, N. Mahood & D. Kinchington
- 255 **Anti-herpes virus activity of 5-methoxymethyl-2'-deoxycytidine in combination with deaminase inhibitors**
P. J. Aduma, S. V. Gupta, A. L. Stuart & G. Tourigny
- 263 **Anti-herpetic activity of (\pm)-(1 α , 2 β , 3 α)-9-[2-hydroxy-3-(hydroxymethyl)cyclobutyl] guanine and inhibition of HSV-1 DNA polymerase**
B. J. Terry, K. E. Mazina, A. V. Tuomari, M. E. Hagen, M. L. Haffey, G. A. Jacobs, R. Zahler & A. K. Field
- 269 **Comparison of the mechanism of toxicity of 3'-azido-3'-deoxythymidine and 3'-fluoro-3'-deoxythymidine in human lymphocytes**
S. Cox & J. Harmenberg

Volume 1, Number 5, 1990

Review

- 279 **An appraisal of the efficacy of the antiviral R61837 in rhinovirus infections in human volunteers**
G. I. Barrow, P. G. Higgins, D. A. J. Tyrrell and K. Andries
- 285 **Enhancement of the antiviral activity of poly (A-U) by adriamycin and daunomycin**
J. M. Jamison, P. J. Bonilla and C.-C. Tsai
- 293 **Effect of daily zidovudine (AZT) pulse-therapy on replication of human immunodeficiency virus type 1 and type 2 *in vitro***
M. W. Vogt, C. Schwarz, H. Kuster, V. Nadai, W. Siegenthaler and R. Lüthy
- 299 **Acute infection of cynomolgus monkeys with Simian immunodeficiency virus (SIV_{sm}) as a model to evaluate antiviral compounds. Effects of 3'-azido,3'-deoxythymidine, foscarnet and 2',3'-dideoxycytidine**
B. Lundgren, E. Ljungdahl Ståhle, D. Böttiger, R. Benthin, K.-G. Hedström, E. Norrby, P. Putkonen, B. Wahren and B. Öberg
- 307 **Synthesis and anti-rhinovirus 1B activity of oxazolinylflavans**
N. Desideri, I. Sestili, M. L. Stein, C. Conti, P. Tomao and N. Orsi
- 313 **The use of antisera to the human herpesvirus 6 major capsid protein to determine the effect of antiviral inhibitors on virus gene expression**
M.-Y. Liu, J. R. Arrand and E. Littler
- 319 **Biochemical pharmacology of 2'-fluoro-2',3'-dideoxyarabinosyladenine, an inhibitor of HIV with improved metabolic and chemical stability over 2',3'-dideoxyadenosine**
M. J. M. Hitchcock, K. Woods, H. De Boeck and H.-T. Ho

Letter to the Editor

- 329 **Changes of HBV markers in serum and liver tissue in patients with chronic hepatitis B treated with recombinant interferon-alpha (rIFN- α): results of a controlled study**
G. Pastore, T. Santantonio, M. Milella, L. Monno, E. Sforza, R. Moschetta, D. Maladorno and D. Criscuolo

Volume 1, Number 6, 1990

- 333 **RNA-intercalating agent interactions: *in vivo* antiviral activity studies**
J. M. Jamison, K. Krabill, K. A. Allen, S. H. Stuart and C.-C. Tsai
- 349 **Treatment of HIV-1 infected patients with peptide T**
I. Julander, B. Alexius, S. Britton, A. Ehrnst, C. Jorup-Rönström, B. Kjellman, Ö. Strannegård, J. Sääf, A. Sönnernborg, L.-O. Wahlund and L. Wetterberg

- 355 **Synthesis and anti-HIV activity of some novel substituted dialkyl phosphate derivatives of AZT and ddCyd**
C. McGuigan, T. J. O'Connor, S. R. Nicholls, S. Nickson and D. Kinchington

- 361 **Inefficient phosphorylation of 3'-fluoro-2',3'-dideoxythymidine in liver cells may explain its lack of inhibition of duck hepatitis B virus replication *in vivo***
B. Löfgren, A. Habteyesus, E. Nordenfelt, S. Eriksson and B. Öberg

- 367 **Pharmacokinetics of 3'-azido-2',3'-dideoxy-5-methylcytidine in rats**
F. D. Boudinot, S. S. Ibrahim, Y. Qin, C. K. Chu and R. F. Schinazi

Short communication

- 373 **Novel sensitivity of acyclovir-resistant varicella-zoster virus to anti-herpetic drugs**
K. Shiraki, J. Namazue, T. Okuno, K. Yamanishi and M. Takahashi

Indexes

- 377 **Subject index**
379 **Author index**